Literature DB >> 34594011

Comment on: 'Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae'.

Tomoyuki Kawada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34594011      PMCID： PMC9232510          DOI： 10.1038/s41433-021-01779-5

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  5 in total

1.  Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study.

Authors:  A T Touhouche; M Cassagne; E Bérard; F Giordano-Labadie; A Didier; P Fournié; C Paul; M Tauber
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-27       Impact factor: 6.166

2.  Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis.

Authors:  Jacob P Thyssen; Peter B Toft; Anne-Sofie Halling-Overgaard; Gunnar H Gislason; Lone Skov; Alexander Egeberg
Journal:  J Am Acad Dermatol       Date:  2017-08       Impact factor: 11.527

Review 3.  Ocular surface disease associated with dupilumab treatment for atopic diseases.

Authors:  Canan Asli Utine; Gavin Li; Penny Asbell; Stephen Pflugfelder; Esen Akpek
Journal:  Ocul Surf       Date:  2020-05-18       Impact factor: 5.033

4.  Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy.

Authors:  Ayaka Kimura; Ayaka Takeda; Toyo Ikebukuro; Junko Hori
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-02-15

5.  Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae.

Authors:  Magdalena Z Popiela; Ramez Barbara; Andrew M J Turnbull; Emma Corden; Beatriz Suarez Martinez-Falero; Daniel O'Driscoll; Michael R Ardern-Jones; Parwez N Hossain
Journal:  Eye (Lond)       Date:  2021-01-28       Impact factor: 3.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.